Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Ecabet API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ecabet | CAS No: 33159-27-2 | GMP-certified suppliers
A medication that treats reflux oesophagitis and peptic ulcer disease by protecting the gastric mucosa and inhibiting Helicobacter pylori activity.
Therapeutic categories
Primary indications
- For the treatment of reflux oesophagitis and peptic ulcer disease
Product Snapshot
- Ecabet is an oral small molecule formulation
- It is primarily indicated for the treatment of reflux oesophagitis and peptic ulcer disease
- The product is currently in the investigational stage and has not received regulatory approval
Clinical Overview
Pharmacologically, Ecabet belongs to the terpene class of organic compounds, specifically diterpenoids composed of four isoprene units. Its mechanism of action in the gastrointestinal tract involves inhibition of Helicobacter pylori, a major pathogenic factor in peptic ulcer disease. Ecabet reduces H. pylori survival by inhibiting key bacterial enzymes including NADPH oxidase and urease, enzymes critical for bacterial adhesion and colonization of the gastric mucosa. Additionally, Ecabet inhibits pepsin activity, contributing to protection of the mucosal barrier against acidic gastric secretions.
In ophthalmology, Ecabet promotes increased production and secretion of mucin from conjunctival goblet cells and corneal epithelial cells. Mucin is an essential glycoprotein component of tear film that provides lubrication and reduces tear evaporation, addressing the pathophysiology of dry eye syndrome.
Key pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) for Ecabet are incompletely characterized, particularly for the ocular route. No extensive human safety or toxicity data have been published beyond its established gastrointestinal indications. Given its enzymatic targets and protective mucosal effects, monitoring for adverse effects related to altered gastric flora or hypersensitivity is prudent during clinical use.
Ecabet’s application in both gastrointestinal and ocular indications demonstrates its multifaceted pharmacology. Currently, it is marketed predominantly in Asia with limited regulatory approvals globally.
For API sourcing, quality control should emphasize purity, consistent stereochemistry typical of diterpenes, and absence of residual solvents or contaminants. Suppliers should provide detailed certificates of analysis and comply with relevant Good Manufacturing Practices (GMP) to ensure batch-to-batch reproducibility suitable for pharmaceutical formulation and regulatory submissions.
Identification & chemistry
| Generic name | Ecabet |
|---|---|
| Molecule type | Small molecule |
| CAS | 33159-27-2 |
| UNII | 2K02669KWP |
| DrugBank ID | DB05265 |
Pharmacology
| Summary | Ecabet acts primarily by inhibiting Helicobacter pylori enzymes, including urease and NADPH oxidase, reducing bacterial adhesion to the gastric mucosa. It also inhibits pepsin activity, contributing to the protection of the gastric mucosal barrier. These mechanisms target key factors involved in peptic ulcer disease and reflux oesophagitis. |
|---|---|
| Mechanism of action | Ecabet reduces the survival of H. pylori in the stomach and inhibits pepsin activity in the gastric juice of experimental animals. Here we have investigated the effects of ecabet on some of the factors involved in the dynamics of the mucosal barrier, i.e. pepsins and mucins. Pepsin, acid and Helicobacter pylori are major factors in the pathophysiology of peptic ulcer disease and reflux oesophagitis. Ecabet also acts as an inhibitor of H. pylori NADPH oxidase as well as urease. Inhibition of these enzymes prevents bacterial adhesion to gastric mucosa. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Urease subunit alpha | Enterobacter aerogenes | inhibitor |
| NADPH oxidase organizer 1 | Humans | antagonist |
Formulation & handling
- Ecabet is a small molecule diterpenoid with low aqueous solubility, indicating potential challenges in oral formulation bioavailability.
- Due to its high logP value (4.93), formulation strategies should consider lipid-based systems or solubilization techniques to enhance absorption.
- As a solid with limited water solubility, careful handling and storage under controlled humidity may be required to maintain stability.
Regulatory status
Ecabet is a type of Mucosa protectants
Mucosa protectants are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various gastrointestinal disorders. These specialized compounds play a crucial role in protecting and healing the mucous membranes lining the digestive tract.
Mucosa protectants act by forming a protective barrier on the mucosal surface, shielding it from irritants and corrosive substances. They are commonly employed to treat conditions such as gastric ulcers, gastroesophageal reflux disease (GERD), and gastritis. By safeguarding the delicate mucosa, these APIs promote the natural healing process and reduce inflammation.
One prominent mucosa protectant is sucralfate, which functions by binding to damaged tissue and creating a physical barrier that shields it from gastric acid and enzymes. This protection allows the injured mucosa to regenerate and restore its integrity.
Another commonly used mucosa protectant is bismuth subsalicylate. It possesses anti-inflammatory properties and acts as a local antacid, reducing the secretion of acid in the stomach. This dual action aids in relieving symptoms associated with peptic ulcers and other gastrointestinal disorders.
Mucosa protectants can be administered orally in the form of tablets, suspensions, or chewable tablets. They are often combined with other APIs, such as proton pump inhibitors or antacids, to enhance their therapeutic efficacy.
In conclusion, mucosa protectants are a crucial subcategory of pharmaceutical APIs that provide a protective shield to the gastrointestinal mucosa, aiding in the treatment of various digestive disorders. Their ability to promote mucosal healing and reduce inflammation makes them invaluable in gastroenterology and related fields.
Ecabet (Mucosa protectants), classified under Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
Ecabet API manufacturers & distributors
Compare qualified Ecabet API suppliers worldwide. We currently have 1 companies offering Ecabet API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Nakoda Chemicals | Producer | India | India | CoA, JDMF | 6 products |
When sending a request, specify which Ecabet API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Ecabet API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
